-
11/24/2023
PAION AG cancelled guidance for financial year 2023
-
10/26/2023
PAION AG: Filing an application for the opening of insolvency proceedings
-
10/19/2023
PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights
-
10/13/2023
PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
-
08/14/2023
Tilmann Bur succeeds Gregor Siebert as CEO of PAION AG
-
04/03/2023
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
-
01/27/2023
PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults